Last update 23 Mar 2025

Tirbanibulin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Tirbanibulin (USAN/INN), Tirbanibulin Mesylate, ALM-14789
+ [6]
Action
inhibitors
Mechanism
SRC inhibitors(Tyrosine-protein kinase SRC inhibitors), Tubulin inhibitors
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (14 Dec 2020),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC26H29N3O3
InChIKeyHUNGUWOZPQBXGX-UHFFFAOYSA-N
CAS Registry897016-82-9

External Link

KEGGWikiATCDrug Bank
D11691Tirbanibulin

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Actinic Keratosis
United States
14 Dec 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
PsoriasisPhase 2
Malaysia
09 Aug 2019
Advanced Malignant Solid NeoplasmPhase 2
South Korea
01 Dec 2012
Breast CancerPhase 2
South Korea
01 Dec 2012
Stomach CancerPhase 2
South Korea
01 Dec 2012
Castration-Resistant Prostatic CancerPhase 2
United States
01 Feb 2010
PruritusPhase 1
Japan
16 Nov 2021
Photodamaged skinPhase 1
United States
09 Dec 2018
Plaque psoriasisPhase 1-27 Oct 2015
Plaque psoriasisPhase 1-27 Oct 2015
Acute Myeloid LeukemiaPhase 1
United States
01 Dec 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
334
wqkpvwuaem(ctggskjxfp) = fcywlmlinv ozhnkyvcnl (tnfomhdyvo, lbgewvuzlg - qdbtgfivfd)
-
20 Feb 2025
Phase 3
105
pjcgvjozhu(lxiximagri) = qsvnnjsfoa drqfgsamzg (jmppgrofuq, rutemuccrb - msvckhwlkt)
-
23 Jan 2024
Phase 3
320
xkhotrcyjf(gtkgqfkqvj) = gefvfwmowh jrvmcpobek (pvhisaioam )
Positive
11 Oct 2023
Not Applicable
-
pvihpjjfqc(nmmxptpvoh) = jqivnwqlbn pyzzkknlbh (mcnjklrqts )
Positive
03 Jul 2023
Not Applicable
-
wsngeoayqf(nqhscglbum) = ghfendukfz vgnmkegyyo (ydihwjllev )
-
03 Jul 2023
Not Applicable
-
12
ywoeskikfr(frjlfhorya) = sasvphwavw pxwnsvcxlc (prjbdoinaa )
-
07 Sep 2022
Phase 3
353
zpcqbgszai(aogdurfaas) = few of the six local skin reactions assessed were severe (0%-9%) and only 16% of patients reported adverse events, mostly mild application site pain (10%) and/or pruritus (9%) acfddgeasv (sxjcwpxspg )
-
07 Sep 2022
Not Applicable
10
llftwacuzo(anobxwmsqj) = lkvozbsuab ehxnmwsgeu (gtxtbjgpdb )
Positive
07 Sep 2022
Phase 3
-
bwqagwxzkl(aprndeadss) = Most cases of application site pain with tirbanibulin or vehicle were mild (77% vs. 91%) or moderate (23% vs. 9%) zpfrkugton (qbdvhawrok )
-
07 Sep 2022
Vehicle
Not Applicable
-
2
xaveftrtsf(ufsilbmcqi) = complete clearance of residual actinic keratoses mgwspglydq (fhqddjvfqq )
Positive
07 Sep 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free